New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 16, 2013
13:55 EDTA, A, STJ, STJ, NUVA, NUVA, JNJ, JNJ, EW, EW, COV, COV, BCR, BCR, BAX, BAX, AFFX, AFFX, SYK, SYKBofA/Merrill's healthcare analysts to hold an analyst/industry conference call
Medical Technology Analyst Hopkins, Life Science Tools Analyst de Bruin and Ketner preview 4Q12 earnings season and discuss upcoming catalysts such as Covidien's spin-off of Mallinckrodt, on an Analyst/Industry conference call to be held on January 16 at 2 pm.
News For A;AFFX;BAX;BCR;COV;EW;JNJ;NUVA;STJ;SYK From The Last 14 Days
Check below for free stories on A;AFFX;BAX;BCR;COV;EW;JNJ;NUVA;STJ;SYK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
August 31, 2014
13:53 EDTSTJSt. Jude Medical Quartet quadripolar lead performed better than bipolar leads
Subscribe for More Information
13:23 EDTBAXGoldman to hold a conference
Subscribe for More Information
12:50 EDTEWEuropean Society of Cardiology to hold a conference
Subscribe for More Information
August 28, 2014
17:42 EDTJNJ, STJJ&J begins sales process for its medical device unit Cordis, WSJ says
Subscribe for More Information
07:05 EDTCOVCovidien acquires Sapheon, terms not disclosed
Covidien announced that it has acquired Sapheon, Inc., a privately-held developer of venous disease treatments. Financial terms of the transaction were not disclosed.
August 27, 2014
09:08 EDTBAXNektar could see $100M in revenue from Baxter drug, says Roth Capital
Roth Capital believes that Baxter's (BAX) BAX-855 drug delivered compelling Phase III data, and the firm expects the drug to compete effectively against Biogen's (BIIB) Eloctate. Roth expects BAX-855 to launch in 1Q16 and believes it could generate up to $100M in annual revenue for Nektar. The firm keeps a $21 price target and Buy rating on Nektar.
August 26, 2014
19:33 EDTCOVCovidien shareholder sues to block sale to Medtronic, Bloomberg reports
Subscribe for More Information
16:29 EDTSTJSt. Jude Medical resolves FDA warning letter for Plano facility
Subscribe for More Information
07:31 EDTNUVAWilliam Blair to hold a field trip
Subscribe for More Information
August 25, 2014
08:27 EDTJNJJanssen Affiliate Cilag acquires Covagen, terms not disclosed
Subscribe for More Information
07:03 EDTJNJVIVUS acquires patents from Janssen Pharmaceuticals
VIVUS (VVUS) announced the acquisition of a group of patents from Janssen Pharmaceuticals (JNJ) covering uses of topiramate as monotherapy and in combination with other pharmaceutical agents to treat a variety of medical conditions. Janssen has agreed to dismiss the lawsuit it brought against VIVUS on August 22, 2014 in the U.S. District Court for the District of Delaware. VIVUS will pay a one-time upfront fee and a royalty to Janssen on Qsymia product sales for an assignment of these topiramate-related patents owned by Janssen. VIVUS has an option to buy out the royalty for a predetermined amount.
August 24, 2014
21:54 EDTNUVA, EWPiper Jaffray to hold a bus tour
Subscribe for More Information
August 22, 2014
07:01 EDTCOVCovidien acquires Reverse Medical, terms not disclosed
Subscribe for More Information
August 21, 2014
15:37 EDTBAXNektar: Baxter announces positive results from Phase 3 study of BAX 855
Nektar Therapeutics (NKTR) reports Baxter International (BAX) announced positive results from its Phase 3 pivotal clinical trial of BAX 855, an investigational, extended half-life recombinant factor VIII treatment for hemophilia A based on ADVATE, which met its primary endpoint in reducing annualized bleed rates in the prophylaxis arm compared to the on-demand arm. Top-line results from the prospective, global, multi-center Phase 3 study demonstrated that BAX 855 met its primary endpoint in the control and prevention of bleeding, routine prophylaxis and perioperative management for patients who were 12 years or older. Patients in a twice-weekly prophylaxis arm experienced a 95 percent reduction in median ABR as compared to those in the on-demand arm (1.9 vs. 41.5, respectively). BAX 855 was also effective in treating bleeding episodes, 96 percent of which were controlled with one or two infusions. The half-life of BAX 855 was 1.4 - 1.5 times that of ADVATE, consistent with the findings from the Phase 1 study. No patients developed inhibitors to BAX 855 and no treatment-related serious adverse events, including hypersensitivity, were reported. The most common product-related adverse event was headache. Baxter expects to submit a Biologics License Application for BAX 855 to the U.S. Food and Drug Administration before the end of 2014 and will present additional data in the coming months. In addition to an ongoing continuation study for patients who have completed the pivotal trial, the company is initiating a Phase 3, prospective, open-label, multi-center study to evaluate the safety and efficacy of BAX 855 among 60 previously treated patients under the age of 12 with severe hemophilia A. Consistent with guidelines published by the European Medicines Agency that require a study in children less than 12 years of age prior to filing, Baxter expects to file a Marketing Authorization Application with the EMA upon the completion of the pediatric study
09:02 EDTBAXBaxter announces BAX 855 met primary endpoint in Phase 3 study
Baxter announced "positive" results from its Phase 3 pivotal clinical trial of BAX 855, which met its primary endpoint in reducing annualized bleed rates in the prophylaxis arm compared to the on-demand arm. Top-line results from the prospective, global, multi-center Phase 3 study demonstrated that BAX 855 met its primary endpoint in the control and prevention of bleeding, routine prophylaxis and perioperative management for patients who were 12 years or older. Patients in a twice-weekly prophylaxis arm experienced a 95% reduction in median ABR as compared to those in the on-demand arm. BAX 855 was also effective in treating bleeding episodes, 96% of which were controlled with one or two infusions. The half-life of BAX 855 was 1.4 – 1.5 times that of ADVATE, consistent with the findings from the Phase 1 study. No patients developed inhibitors to BAX 855 and no treatment-related serious adverse events, including hypersensitivity, were reported. The most common product-related adverse event was headache. Baxter expects to submit a Biologics License Application for BAX 855 to the U.S. Food and Drug Administration before the end of 2014 and will present additional data in the coming months. In addition to an ongoing continuation study for patients who have completed the pivotal trial, the company is initiating a Phase 3, prospective, open-label, multi-center study to evaluate the safety and efficacy of BAX 855 among 60 previously treated patients under the age of 12 with severe hemophilia A. Consistent with guidelines published by the European Medicines Agency that require a study in children less than 12 years of age prior to filing, Baxter expects to file a Marketing Authorization Application with the EMA upon the completion of the pediatric study.
08:29 EDTEWEdwards Lifesciences price target raised to $120 from $97 at JMP Securities
Subscribe for More Information
05:42 EDTJNJIllumina announces strategic partnership with AstraZeneca, Sanofi, Janssen
Illumina (ILMN) announced it has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing, or NGS,-based oncology test system. The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine. Initial strategic partners include AstraZeneca (AZN), Janssen Biotech, a Johnson & Johnson (JNJ) company, and Sanofi (SNY). Illumina is working with the strategic partners to develop assays that detect and measure multiple variants simultaneously to support partners’ clinical trials, with the objectives of securing regulatory agency approvals and test commercialization. In parallel, Illumina is working with key thought leaders to set standards for NGS-based assays in routine clinical oncology practice, as well as to define regulatory frameworks to enable this new testing paradigm. Together, Illumina and its strategic partners aim to transition from single-analyte companion diagnostics to panel-based assays that select for “companion therapeutics.”
August 20, 2014
07:18 EDTCOVMedtronic shares have upside with or without deal, says Deutsche Bank
Deutsche Bank sees limited downside risk and significant upside potential for shares of Medtronic (MDT), with or without the pending Covidien (COV) acquisition. Deutsche says the Q1 results show improving trends and it keeps a Buy rating on Medtronic with an $85 price target.
August 19, 2014
16:33 EDTBAXBaxter to expand Alabama facility to increase dialyzers production
Subscribe for More Information
08:22 EDTCOVMedtronic: We will continue to pay significant US taxes following Covidien deal
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use